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Reduced brain metabolism is an invariant feature of
Alzheimer Disease (AD) that is highly correlated to the decline
in brain functions. Decreased activities of key tricarboxylic acid
cycle (TCA) cycle enzymes may underlie this abnormality and
are highly correlated to the clinical state of the patient.
The activity of the ␣-ketoglutarate dehydrogenase complex
(KGDHC), an arguably rate-limiting enzyme of the TCA cycle,
declines with AD, but the mechanism of inactivation and
whether it can be reversed remains unknown. KGDHC consists
of multiple copies of three subunits. KGDHC is sensitive to oxidative stress, which is pervasive in AD brain. The present studies
tested the mechanism for the peroxynitrite-induced inactivation and subsequent reactivation of purified and cellular
KGDHC. Peroxynitrite inhibited purified KGDHC activity in a
dose-dependent manner and reduced subunit immunoreactivity and increased nitrotyrosine immunoreactivity. Nano-LCMS/MS showed that the inactivation was related to nitration of
specific tyrosine residues in the three subunits. GSH diminished
the nitrotyrosine immunoreactivity of peroxynitrite-treated
KGDHC, restored the activity and the immunoreactivity for
KGDHC. Nano-LC-MS/MS showed this was related to de-nitration of specific tyrosine residues, suggesting KGDHC may have a
denitrase activity. Treatment of N2a cells with peroxynitrite for
5 min followed by recovery of cells for 24 h reduced KGDHC
activity and increased nitrotyrosine immunoreactivity. Increasing cellular GSH in peroxynitrite-treated cells rescued KGDHC
activity to the control level. The results suggest that restoring
KGDHC activity is possible and may be a useful therapeutic
approach in neurodegenerative diseases.

Although part of classical biochemistry, the tricarboxylic
acid (TCA)2 cycle has recently received considerable atten-
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tion due to its significant roles in diminished glucose metabolism that accompanies neurodegenerative diseases including Alzheimer disease (AD). Oxidants that are increased in
neurodegenerative diseases have been shown to regulate the
TCA cycle enzymes at multiple levels. For example, oxidants
modulate expression of genes in the TCA cycle (1–3) and alter
enzyme activity (4 – 8). The experiments in this manuscript
examine the post-translational modifications of one of these
enzymes.
The current studies focus on the ␣-ketoglutarate dehydrogenase complex (KGDHC) because it is reduced in multiple
neurodegenerative diseases and is sensitive to a variety of oxidants. KGDHC is arguably the rate controlling enzyme complex in the TCA cycle. KGDHC consists of multiple copies
of three subunits: ␣-ketoglutarate dehydrogenase (E1k, EC
1.2.4.2), dihydrolipoyl succinyltransferase (E2k, EC 2.3.1.61),
and dihydrolipoyl dehydrogenase (E3, EC 1.6.4.3). In Escherichia coli, multiple copies of E1k (12 dimers) and E3 (6 dimers)
are arranged along the edges and faces, respectively, of an octahedral E2k core (24 subunits) to form a multienzyme complex
with a molecular weight of around 5 ⫻ 106 dalton (9). The
precise molecular weight and subunit composition of KGDHC
and how it may vary with function in mammalian systems
remains unknown.
The mechanism of the inactivation of KGDHC in disease is
unknown. Diminished activity of KGDHC occurs in a number
of neurodegenerative diseases including AD (10, 11), Parkinson
disease (12) and progressive supranuclear palsy (13, 14). The
relations are most extensively studied in AD in which impaired
glucose metabolism and enhanced oxidative stress exist (15–
19). In AD patients, the diminished activities of KGDHC and
other TCA cycle enzymes are highly correlated to the clinical
dementia rating score before the patients died (20). This suggests that these TCA cycle enzymes may play a role in the
pathophysiology of AD. Thus, understanding the mechanism
by which these enzymes are altered in these diseases would
contribute to the knowledge of the disease pathology. The current studies focus on one of these enzymes, KGDHC. One subunit of the KGDH complex, E3, is shared with the pyruvate
dehydrogenase complex (PDHC).

dihydrolipoyl dehydrogenase; ROS, reactive oxygen species; RNS, reactive
nitrogen species; PDHC, pyruvate dehydrogenase complex; PTM, post-translational modification.
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Nitration of KGDHC
Post-translational modification (PTM) of proteins has been
proposed to be involved in the pathogenesis of many diseases
including neurodegenerative diseases. A commonly found oxidative modification in neurodegenerative diseases is the nitration of tyrosines, which is mainly induced by peroxynitrite (21).
Excessive nitration occurs in brains of patients that died with
AD. Peroxynitrite is a reactive nitrogen species (RNS) formed
by the near diffusion-limited reaction of superoxide with nitric
oxide (22, 23). Superoxide can be generated from the mitochondrial electron chain and KGDHC. Nitric oxide is produced by
the three isoforms of the nitric-oxide synthase. KGDHC is inactivated by reactive oxygen species (ROS) (6). For example,
hydrogen peroxide inactivates KGDHC activity in intact cardiac mitochondria, fibroblasts, and N2a cells (4, 5, 7, 8). Peroxynitrite reduces KGDHC activity and selectively alters
immunoreactivity of E1k and E2k (24). However, the inhibitory
mechanism of KGDHC by peroxynitrite including possible
post-translational modification has not been reported. This
could be due to the complexity and low abundance of KGDHC
in brain, which has made identification of exact modification
sites of KGDHC by mass spectrometry very difficult.
We focused these studies on nitration because it is stable over
a long time of period compared with other labile modifications
such as S-nitrosation or glutathionylation. Nitration is likely to
be reversed as growing evidence supports the denitration of
proteins in many biological systems including tissue homogenates, activated macrophages and crude extracts from different
organs (25–30). However, the molecular identity of the denitrase activity is still unknown.
The large molecular weight and complex structure of
KGDHC makes investigation of its oxidative modifications
difficult. Thus, the current experiments employed multiple
approaches. Clear- or Blue-Native gel has the advantage of
allowing the study of protein complexes with molecular weight
up to 10 MDa and preserving enzyme activity after electrophoresis (31). By combining proteomic tools including denaturing
and native gel electrophoresis and a nano-LC-MS/MS system,
the current studies tested whether distinct nitration sites
underlie the oxidant induced deficits in KGDHC and whether
the resulting nitration could be reversed.

EXPERIMENTAL PROCEDURES
Purification and Treatment of KGDHC—KGDHC (200 l;
Cat No. K1502; Sigma) was further purified by loading the protein onto a 2% ABT agarose column (0.7 ⫻ 50 cm) (Agarose
Bead Technologies, Tampa, FL) to remove bovine serum albumin. The five fractions with the highest KGDHC activity from
four column purifications were pooled and treated with 0, 1, or
10 M peroxynitrite (Cayman, Ann Arbor, MI) at 37 °C for 15
min. Samples were then concentrated using an Amicon
Ultra-15 Centrifugal Filter Unit 100 (Millipore; Billerica, MA).
The concentrated samples were immediately processed for
KGDHC activity measurement, SDS gel, Clear- or Blue-native
gel electrophoresis and Western blotting detection.
In experiments testing the reversal of nitration by GSH, purified KGDHC was treated with 0 and 10 M peroxynitrite at
37 °C for 15 min (two identical reactions were included for the
10 M peroxynitrite treatment). Then, 5 mM GSH was added to
MAY 20, 2011 • VOLUME 286 • NUMBER 20

one of the peroxynitrite-treated samples. All samples including
0, 10 M peroxynitrite, and 10 M peroxynitrite ⫹ 5 mM GSH
were incubated for another 15 min at 37 °C. All samples were
then processed as described in the previous paragraph.
Cell Culture and Treatment—N2a neuroblastoma cells were
purchased from American Type Culture Collection (Manassas;
VA). The cells in 100-mm dish were maintained at 37 °C in a
humidified incubator under 5% CO2 and 95% air in the complete medium (DMEM supplemented with 10% fetal bovine
serum). Cells were treated with peroxynitrite as described previously with slight modification (32) Cells were treated with
different concentrations of peroxynitrite (0, 0.0625, 0.125, 0.25,
0.5, and 1 mM) for 5 min and allowed to recover in normal
medium or medium containing 1 mM NAC for 24 h. Cells were
harvested and the KGDHC activity was measured in cell lysates.
Detailed methods are described in supplemental Method S1.
After treatment, cell pellets were processed differently for different measurements (see detailed procedures in each section
below).
KGDHC Activity Measurement—KGDHC catalyzes the following reaction: ␣-ketoglutarate ⫹ NAD⫹ ⫹ CoA 3 succinyl
CoA ⫹ CO2 ⫹ NADH. Two independent, well established
assays were used to measure KGDHC activities. Both methods
use the specific substrate ␣-ketoglutarate (␣-KG) to distinguish
NADH production from KGDHC to that from other enzymes
(i.e. substrate specificity). One method assays activity in purified enzyme or cell lysates whereas the other assesses the activity of the enzyme in a clear native gel.
KGDHC Activity Measured in Purified Enzyme and Cell
Lysates—Purified enzyme samples were used directly for
KGDHC activity measurements. Cell pellets were immediately
resuspended with 500 l of lysis buffer (50 mM Tris-HCl, pH
7.2, 0.4% Triton X-100, 0.2 mM EGTA, 50 M leupeptin, and 1
mM DTT) for 30 min with shaking at 4 °C. After the 30-min
incubation, cell lysates were disrupted by repeated aspiration
through a 21-gauge needle for 12 times on ice. KGDHC activity
was assayed as described previously (11).
KGDHC Activity by In-gel Activity Staining—The basis of the
in-gel activity staining is very similar to the lysis method except
that the reducing equivalents are coupled to nitroblue tetrazolium (NBT) (33). The specificity again depends upon the substrate. Equal amount of samples (10 g) were loaded to clear
native gels. After electrophoresis, the clear native gel was
washed once with the reaction mixture (50 mM Tris, pH 7.6; 1
mM MgCl2, 0.1 mM CaCl2, 0.05 mM EDTA, 0.2% Triton X-100,
0.3 mM TPP, 5 g/ml rotenone in ethanol, and 3.5% polyvinylalcohol). Then 10 ml of assay mix (3 mM ␤-NAD, 1 mM CoA, 3
mM ␣-KG, 0.75 mM NBT, 0.05 mM phenazine methosulfate
(PMS) in reaction mixture) was added to the gel to stain the
KGDHC activity. An assay mix without CoA and ␣-KG was
added to a duplicate gel and used as the blank. After a 5-min
incubation at room temperature, the reaction was stopped by
washing the gel with distilled water.
SDS-gel, Blue, or Clear Native Gel Electrophoresis and Western Blotting—For SDS-PAGE, a 5⫻ SDS-sample loading dye
(50% glycerol, 250 mM Tris (pH 6.8), 10 mM EDTA, 10% SDS,
and 0.04% bromphenol blue) was added to either purified
enzyme or cell lysates to achieve 1⫻ final concentration. ElecJOURNAL OF BIOLOGICAL CHEMISTRY
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trophoresis was done with a 4 –20% Tris-glycine gel (Invitrogen, Carlsbad, CA) using 120 volts for 2.5 h.
For Blue-native gel electrophoresis, NativePAGETM Sample
buffer (4⫻) was added to samples to make 1⫻ final concentration. About 6 g of protein was loaded into each well, and the
electrophoresis was done with a NativePAGETM Novex威
3–12% Bis-Tris gel (Invitrogen) using 50 volts for overnight
according to the manufacturer’s instruction. Unlike Blue-native gel electrophoresis, the cathode buffer for clear native gel
electrophoresis contains no NativePAGETM 20X Cathode
Buffer Additive (0.4% Coomassie威 G-250). Western blotting
was performed as described in supplemental Method S2.
Mass Spectrometry—The protein gel bands were excised
from the SDS or Blue-Native gels. The gel bands were reduced
with 10 mM of DTT and alkylated with 55 mM iodoacetamide,
and then digested with Sequence Grade Modified Trypsin (Promega, Madison, WI) in ammonium bicarbonate buffer at 37 °C
overnight. The digestion products were extracted twice with
0.1% trifluoroacetic acid and 50% acetonitrile and 1.0% trifluoroacetic acid, respectively. The extracted mixture was dried by
SpeedVac and dissolved in 10 l of 0.1% tri-fluoroacetic acid.
Half of the extracts were injected for LC-MS/MS analysis. For
LC-MS/MS analysis, each digestion product was separated by a
60-min gradient elution with the Dionex U3000 capillary/nanoHPLC system (Dionex; Sunnyvale, CA) at a flow rate of 0.250
l/min that is directly interfaced with the Thermo-Fisher
LTQ-Obritrap mass spectrometer (Thermo Fisher, San Jose,
California) operated in data-dependent scan mode. The analytical column was a home-made fused silica capillary column (75
m ID, 100 mm length; Upchurch, Oak Harbor, Washington)
packed with C-18 resin (300 A, 5 m, Varian, Palo Alto, California). Mobile phase A consisted of 0.1% formic acid, and
mobile phase B consisted of 100% acetonitrile and 0.1% formic
acid. The 60 min gradients with 250 nl/min flow rate for B
solvent went from 0 to 55% in 34 min and then in 4 min to 80%.
The B solvent stayed at 80% for another 8 min and then
decreased to 5% in 8 min. Another 6 min was used for equilibration, loading and washing. The mass acquisition method
was one FT-MS scan followed by 6 subsequent MS/MS scan in
the ion trap. The FT-MS scan was acquired at resolution 30,000
in the Orbi-trap. The six most intense peaks from the FT full
scan were selected in the ion trap for MS/MS. Data were analyzed using the MASCOT software search algorithm and manual inspection. Nitrated peptides and un-nitrated peptides are
chemically similar to one another, and it is reasonable to expect
that they exhibited similar ionization efficiencies. The relative
quantification of nitrated tyrosines and un-nitrated tyrosines
was accomplished by comparing the peak intensity of the corresponding nitrated peptides and unnitrated peptides.
Purification of KGDHC from N2a—All procedures were carried out at 4 °C unless otherwise indicated. Mitochondria were
isolated from N2a cells by modification of a previous method
(34). Detailed methods are described in supplemental Method
S3. Mitoplast preparation (35) and KGHDC purifications are
described in supplemental Method S4.
Immunoprecipitation of Nitrated KGDHC from N2a Cells—
Immunoprecipitation (IP) was utilized to pull down nitrated
KGDHC from N2a cells treated with peroxynitrite. Cell pellets
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(see “Cell Culture and Treatment”) were resuspended in 2 ml of
ice-cold RIPA buffer (50 mM Tris HCl, pH 8, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) and
incubated at 4 °C for 30 min. Then cells were disrupted by
repeated aspiration through a 21-gauge needle. Cellular debris
were pelleted by centrifugation at 10,000 ⫻ g for 10 min at 4 °C.
Supernatants were saved, and the pellets were resuspended
with 0.5 ml of RIPA buffer and subjected to above steps to
re-extract cellular proteins. Supernatants combined from two
centrifugations were precleared by adding 1.0 g of normal
mouse IgG and 20 l of resuspended protein A/G PLUS-agarose beads (Santa Cruz Biotechnology) followed by incubation
at 4 °C for 30 min. The agarose beads were pelleted by centrifugation at 1,000 ⫻ g for 5 min at 4 °C. Supernatants (1.2 ml)
were transferred to a new 1.5 ml tube and 12.5 l of nitrotyrosine antibody (Abcam; Cambridge, MA, 0.25 g/l) was
added. After incubation at 4 °C for 1 h, 20 l of resuspended
protein A/G PLUS-agarose was added, and the mixture was
incubated at 4 °C on a rocking platform overnight. Immunoprecipitate was collected by centrifugation at 1,000 ⫻ g for 5 min at
4 °C. The pellets were washed three times with 1 ml of RIPA
buffer by incubating the resuspension for 10 min with gently
rocking in the cold room followed by centrifugation (1,000 ⫻
g/5 min). After the final wash, the pellets were resuspended in
40 l of 1⫻ electrophoresis sample buffer and subjected to
SDS-PAGE and Western blotting analyses.
Real-time PCR—Total RNA was isolated from cell pellets by
an RNesay Plus Micro kit (Qiagen, Valencia, CA) according to
the manufacturer’s instruction. First-strand cDNA was synthesized from the isolated total RNA using a Transcriptor First
Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN) with anchored oligo(dT)18 as primer. Real-time PCR of
E1k, E2k, and E3 was performed using an Applied Biosystems
7500 Fast Real-Time PCR system with pre-designed Taqman威
gene expression assays (Applied Biosystems, Foster City, CA)
by modification of a published method (36) as described in supplemental Method S5.

RESULTS
Inhibition of Purified KGDHC by Peroxynitrite—Treatment
of purified KGDHC with peroxynitrite inhibited KGDHC activity in a dose-dependent manner (Fig. 1). Peroxynitrite, as low as
1 M, diminished KGDHC activity by 40% (Fig. 1A). Similarly, 1
M peroxynitrite reduced KGDHC activity by 42% as measured
by in gel activity staining (Fig. 1B).
Nitration of Purified KGDHC by Peroxynitrite—Whether
peroxynitrite induces nitration of KGDHC was determined by
SDS gel electrophoresis followed by Western blotting using an
anti-nitrotyrosine antibody (Fig. 2A). The lower concentration
of peroxynitrite (1 M) significantly reduced the immunoreactivity of E1k only (Fig. 2B). While the immunoreactivities of
E1k, E2k, and E3 were all decreased significantly in response to
the higher concentration of peroxynitrite (10 M) (Fig. 2B). In
contrast, the immunoreactivity of nitrotyrosine increased with
increasing concentration of peroxynitrite (Fig. 2, A and B).
Western blotting following blue-native gel electrophoresis
was also utilized to determine the nitration of KGDHC. Higher
shifted bands occurred in all three subunits of KGDHC that
VOLUME 286 • NUMBER 20 • MAY 20, 2011
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were treated with peroxynitrite as compared with untreated
ones (Fig. 3). Multiple up shifted bands (greater than the 1263kDa band) were mainly observed in 10 M peroxynitrite-treated
KGDHC. They are likely the up-shifted subunits that are
nitrated by peroxynitrite. Similarly, the immunoreactivity of
nitrotyrosine increased with increasing concentration of
peroxynitrite.
Tryrosine 175, 556 of E1k, 313 of E2k, and 352, 416 of E3 Are
the Targets of Peroxynitrite—The modification sites in KGDHC
were further investigated by nano-LC-MS/MS mass spectro-

FIGURE 1. Peroxynitrite inhibited KGDHC activity in a dose-dependent
manner. The effects of peroxynitrite on the KGDHC activity were measured in
a plate reader (A) and in a Clear Native gel (B). B includes a representative
in-gel activity staining of KGDHC (left panel) and a bar graph (right panel).
Values are means ⫾ S.E. from three independent experiments done in triplicate. Values with different letters vary significantly (p ⬍ 0.05) as determined
by a one-way ANOVA followed by a Student-Newman-Keul’s test.

metry. Purified KGDHC was incubated with peroxynitrite and
then processed for SDS and/or Blue native gel electrophoresis.
The bands were cut and analyzed by nano-LC-MS/MS mass
spectrometry.
The tyrosine in positions Tyr-175 and Tyr-556 in E1k of
KGDHC were nitrated by peroxynitrite as determined by both
MS and MS/MS analysis. For example, the mass of a peptide
ion at m/z 758.85 matches to the mass of the nitrated
172
LGFY*GLDESDLDK184, in which the peptide mass has the
45 dalton mass increase corresponding to the incorporation of
a -NO2 group in the peptide. The MS/MS spectrum of this
peptide ion at 758.85 allowed us to determine that Tyr-175 was
nitrated as shown in Fig. 4. Following a similar procedure, the
residue Tyr-313 in E2k (supplemental Fig. S1A) and the residues Tyr-352 and Tyr-416 (supplemental Fig. S1B) in the E3
subunit of KGDHC were also found to be nitrated by peroxynitrite. Furthermore, the percent nitrated tyrosine in the
three subunits of KGDHC was calculated by using a relative
quantitative method (see “Experimental Procedures”). MSidentified nitration sites and the percentage of nitrated tyrosine in each subunit are summarized in Table 1. The percent
of nitration in Tyr-175 and Tyr-556 of E1k is 19 and 23%,
respectively. The percent of nitration in Tyr-313 of E2k is
39%. The percent nitration in Tyr-352 and Tyr-416 in E3 is
13 and 46%, respectively.
Denitration of the Nitrated Purified KGDHC—If the nitration serves as a signal, then it should be reversible. KGDHC that
is inactivated by H2O2 or oxidant can be reactivated with glutathione (8). Thus, reduced glutathione (GSH) was added
after treatment of KGDHC with peroxynitrite to determine
whether glutathione would alter the nitration. The consequences on KGDHC were assessed by measuring the change
in KGDHC activity and by Western blotting with the antinitrotyrosine antibody. Peroxynitrite (10 M) reduced
KGDHC activity by 74% (Fig. 5A). Addition of GSH after

E1k
nitrotyrosine
merge

Peroxynitrite
E1k
NT in E1k
E2k
NT in E2k
E3
NT in E3

E2k
nitrotyrosine
merge

E3

1 µM

0
a

0.48 ± 0.08
a
0.01 ± 0.00
a
0.41 ± 0.06
a
0.04 ± 0.02
a
0.42 ± 0.07
a
0.10 ± 0.05

10 µM
b

0.29 ± 0.02
b
0.28 ± 0.01
ac
0.31 ± 0.01
b
0.12 ± 0.05
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0.32 ± 0.01
b
0.24 ± 0.10

b

0.23 ± 0.06
c
0.71 ± 0.01
bc
0.29 ± 0.05
c
0.84 ± 0.06
bc
0.27 ± 0.07
c
0.66 ± 0.13

nitrotyrosine
merge
Peroxynitrite

0

1

10

FIGURE 2. Western blots of KGDHC separated by SDS-gel and analyzed by densitometry. Purified KGDHC was treated with different concentrations of
peroxynitrite, and subjected to SDS-PAGE followed by Western blotting. A, blots were probed with antibodies to E1k, E2k, or E3 (red) and to nitrotyrosine
(green), respectively. The overlap is represented by yellow. B, densitometry analysis of E1k, E2k, E3 and nitrated subunits of KGDHC from at three independent
Western blots by the Odyssey Infrared Imaging System. a– c, values with different letters in each row are significantly different from each other (p ⬍ 0.05) as
determined with a one-way ANOVA followed by a Student-Newman-Keul’s test.
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TABLE 1
Summary of peroxynitrite-induced modification in purified KGDHC
Peroxynitrite (10 M)-treated KGDHC was subjected to either SDS-gel or Bluenative gel electrophoresis. Protein bands that were cut from gels were digested with
trypsin and subjected to nano-LC-MS/MS to identify modification sites. Tyrosine
175, 556 of E1k, 313 of E2k, and 352, 416 of E3 were nitrated by peroxynitrite. The
relative quantification of nitrated tyrosines and un-nitrated tyrosines was accomplished by comparing the peak intensity of the corresponding nitrated peptides and
un-nitrated peptides.
Subunit Modification
E1k

Nitration

E2k
E3

Nitration
Nitration

aa

% Nitration

Y175
Y556
Y313
Y352
Y416

19
23
39
13
46

Type of Gel/digestion
SDS gel/Blue-native gel/trypsin
SDS gel/Blue-native gel/trypsin
SDS-gel/Blue-native gel/trypsin
SDS gel/trypsin
SDS gel/trypsin

E1k
nitrotyrosine

FIGURE 3. Western blots of KGDHC separated by Blue-native gel. Purified
KGDHC was treated with different concentrations of peroxynitrite, and subjected to a Blue-native gel followed by Western blotting. The blots were
probed with antibodies to E1k, E2k or E3 (red) and to nitrotyrosine (green),
respectively. The overlap is represented by yellow.

KGDHC activity
(OD)

0.6

a

merge

a

0.4

E2k
nitrotyrosine

b

0.2

0
Peroxynitrite (10μ M)
GSH (5 mM)

merge

−
−

+
−

+
+

E3
nitrotyrosine
merge
Peroxynitrite (10 μM)
GSH (5 mM)

FIGURE 4. The selected MS/MS spectrum of a nitrated peptide
172
LGFY*GLDESDLDK184 of E1k at m/z 758.85. Purified KGDHC was treated
with 10 M peroxynitrite followed by SDS gel electrophoresis as described
under “Experimental Procedures.” Protein bands corresponding to the E1k
were cut and subjected to trypsin digestion followed by nano-LC-MS/MS
analysis. The mass difference (208.04) between y9 and y10 corresponding to
nitrated tyrosine residue (163.06 ⫹ 45) indicated the nitration of tyrosine 175
in the E1k subunit of KGDHC. The fragment ions match all of the y and b ions
of the peptide, in which the tyrosine (Y) residue was nitrated with a mass
difference of 45Da.

incubation of KGDHC with peroxynitrite restored the activity to levels comparable to those of the untreated KGDHC
(Fig. 5A). Incubation of peroxynitrite-treated KGDHC with
GSH reduced the immunoreactivity of nitrotyrosine (Fig. 5,
B and C).
Mass spectrometry analysis revealed very specific changes in
the reversal of nitration following incubation with GSH. Peroxynitrite induced a 13 and 46% nitration in the Tyr-352 and
Tyr-416, respectively, in E3 (Table 2). The percent nitration in
these two tyrosine residues was reduced to zero following GSH

17644 JOURNAL OF BIOLOGICAL CHEMISTRY

Peroxynitrite (10 µM)

Relative Density

Control

E1k
NT in E1k
E2k
NT in E2k
E3
NT in E3

0.28 ± 0.05
a
0.03 ± 0.02
a
0.35 ± 0.03
a
0.07 ± 0.03
a
0.34 ± 0.02
a
0.07 ± 0.06

a

b

0.08 ± 0.05
b
0.70 ± 0.05
b
0.22 ± 0.04
b
0.78 ± 0.05
b
0.27 ± 0.02
b
0.74 ± 0.07

−
−

+
−

+
+

Peroxynitrite (10 µM)+GSH (5 mM)
c

0.64 ± 0.08
c
0.27 ± 0.05
ac
0.43 ± 0.05
ac
0.15 ± 0.05
ac
0.39 ± 0.04
ac
0.19 ± 0.05

FIGURE 5. Denitration of KGDHC by GSH following peroxynitrite. Purified
KGDHC was treated with 10 M peroxynitrite for 15 min followed by 5 mM GSH
for another 15 min. KGDHC activity was measured. SDS-PAGE followed by
Western blotting was performed. A, KGDHC activity. Values are means ⫾ S.E.
of three independent experiments done in duplicate. Values with different
letters vary significantly (p ⬍ 0.05) as determined by a one-way ANOVA followed by a Student-Newman-Keul’s test. B, representative blots of E1k, E2k,
E3 (red) and nitrotyrosine (green). The yellow reflects overlap. C, densitometry
analysis of E1k, E2k, E3 and nitrated subunits of KGDHC by the Odyssey Infrared Imaging System from at least three independent experiments. a– c, values
with different letters in each row are significantly different from each other
(p ⬍ 0.05) as determined with a one-way ANOVA followed by a StudentNewman-Keul’s test.

incubation (Table 2). While the nitration of E2k (34%) was
reduced by about half after subsequent GSH incubation (15%)
(Table 2).
Nitration of KGDHC in N2a Cells by Peroxynitrite—Peroxynitrite decreased KGDHC activity in a dose-dependent
manner in N2a cells. About a 50% reduction in the activity was
found in cells treated with 0.125 mM (Fig. 6). Moreover, Western blots of KGDHC purified from cell lysates suggested a colocalization of KGDHC with nitrotyrosine (Fig. 7A). The purity of
KGDHC was demonstrated by its significantly higher specific
activity (⬎59 fold) than the starting homogenate (cell lysate).
Immunoprecipitation (IP) of cells after peroxynitrite treatment
with a nitrotyrosine antibody further confirmed the colocalization of KGDHC with nitrotyrosine (Fig. 7B).
Reversal of Nitrated KGDHC in N2a Cells—Subsequent
experiments tested whether the reduction in KGDHC activity
VOLUME 286 • NUMBER 20 • MAY 20, 2011
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TABLE 2
Denitration of KGDHC by GSH following peroxynitrite demonstrated by LC-MS/MS
KGDHC was treated with peroxynitrite or peroxynitrite ⫹ GSH. After treatment, samples were subjected to SDS- PAGE. Protein bands corresponding to the subunits of
KGDHC were cut and further analyzed by mass spectrometry. About half of the nitration of Tyr-313 in E2k was removed after subsequent addition of GSH following
peroxynitrite. Nitration of Tyr-352 and Tyr-416 in E3 induced by peroxynitrite were completely removed following GSH. Underlined Y indicates nitration.
Subunit

Untreated

Peroxynitrite

E2k
% nitration
E3
% nitration

EVVY(313)R
0%
IPNIY(352)AIGD
0%
SEEQLKEEGIEY(416)K
0%

EVVY(313)R
34%
IPNIY(352)AIGD
13%
SEEQLKEEGIEY(416)K
46%

% nitration

FIGURE 6. Peroxynitrite inhibited KGDHC activity in N2a cells. N2a cells
were treated with different concentrations of peroxynitrite (0, 0.0625, 0.125,
0.25, 0.5, and 1 mM) for 5 min and allowed to recover in normal medium for
24 h. Then cells were harvested, and the KGDHC activity was measured in cell
lysates. Values are means ⫾ S.E. of at least two independent experiments
done in triplicate. Values with different letters are significantly different from
each other (p ⬍ 0.05) as determined by a one-way ANOVA followed by a
Student-Newman-Keul’s test.

GSH following peroxynitrite
EVVY(313)R
15%
IPNIY(352)AIGD
0%
SEEQLKEEGIEY(416)K
0%

FIGURE 8. Inactivation of KGDHC by peroxynitrite in N2a cells was
reversed by NAC. N2a cells were first treated with 0.5 mM peroxynitrite for 5
min and the medium was replaced with fresh medium containing 1 mM NAC.
The cells were maintained for another 24 h before harvesting for KGDHC
activity measurement. Values (means ⫾ S.E.) are from at least two independent experiments done in triplicate. Values with different letters are significantly different from each other (p ⬍ 0.05) as determined by a one-way
ANOVA followed by a Student-Newman-Keul’s test.

The reversal of diminished KGDHC by NAC was not mediated at the level of transcription. The levels of mRNA of the
three subunits of KGDHC measured by real-time qPCR showed
a 30% reduction in E1k, a 12% increase in E2k and no change in
E3 in response to peroxynitrite. Addition of NAC to peroxynitrite-treated cells did not alter the mRNA levels of E1k and E2k
as compared with peroxynitrite-treated cells, but NAC reduced
mRNA level of E3 by 20% (Fig. 9).

FIGURE 7. Colocalization of KGDHC and nitrotyrosine following treatment of N2a cells with peroxynitrite. A, representative Western blots of
KGDHC purified from N2a cells after peroxynitrite treatment. B, representative Western blots of N2a cells immunoprecipitated with nitrotyrosine antibody. E1k, E2k, or E3 (red), nitrotyrosine (green), and the yellow reflects
overlap.

following peroxynitrite could be reversed in cultured N2a cells
by N-acetylcysteine (NAC). NAC is the most bioavailable precursor of glutathione, and it has been used widely to increase
GSH level within cells. NAC readily enters cells and is hydrolyzed to cysteine for synthesizing GSH in cells. The reduced
form of glutathione (GSH) has short half-life of less than 1 h in
culture medium (37). The reversal experiments require a 24-h
incubation of cells with glutathione. Thus, the short half-life of
less than 1 h excluded GSH as an optimal thiol compound in
this experiment. Peroxynitrite diminished KGDHC activity by
74% (Fig. 8). Addition of NAC to peroxynitrite-treated cells
rescued KGDHC activity back to control values (Fig. 8).
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DISCUSSION
The present study is the first to identify distinct modification sites in purified KGDHC in response to peroxynitrite.
The closest reported study on KGDHC modification in rat
heart mitochondria only suggests that KGDHC is nitrosated
by NO but without identification of modified residues (38).
Glutathionylation of KGDHC has been demonstrated in cardiac mitochondria treated with H2O2. Lipoic acid, a required
cofactor covalently attached to the E2k subunit, is the site of
glutathionylation (39). KGDHC activity is diminished in a
number of neurodegenerative diseases (11, 13, 40 – 42). The
mechanism of inhibition is unknown in the diseases. Posttranslational modification of the enzyme mediated by oxidative stress, which is associated with these age-related diseases, is likely to contribute to the inhibition under the
disease conditions. The present study explored the underlying mechanism of peroxynitrite induced inhibition and reactivation of KGDHC following peroxynitrite treatment of
either the purified enzyme or cells in culture.
The present study, for the first time, utilized a Blue-native gel
electrophoresis system to study the complex and show that it
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 9. mRNA levels of the subunits of KGDHC in N2a cells treated with
peroxynitrite and peroxynitrite/N-acetylcysteine. Cells were subjected to
total RNA isolation, cDNA synthesis and quantitative real-time RT-PCR. ␤-Microglobulin (␤2m) was used as an internal control. Values are the means ⫾ S.E.
of relative changes over controls from two independent experiments done in
triplicate after normalization to ␤2m. Values with different letters vary statistically from each other (p ⬍ 0.05) as determined by a one-way ANOVA followed by a Student-Newman-Keul’s test.

shifts with stress. The molecular mass of the KGDHC is
unknown in mammalian systems. In E. coli, KGDHC is approximately of 5–10 ⫻ 106 Da based on ratio of 24:24:12 (E1k:E2k:
E3) (43, 44). The three subunits of KGDHC are bound together
tightly through non-covalent bonds. The nature of the dynamic
composition of the complex makes it difficult to determine its
MW in different species precisely (45). In addition, the cellular
physiological state may alter the ratio of the three subunits of
the complex. The shift in bands of KGDHC (Fig. 3) in response
to peroxynitrite suggests that the complex is very dynamic.
Although the physiological consequences are still unknown,
the changes seem to be associated with diminished activity.
Our previous studies showed that KGDHC is sensitive to
peroxynitrite (24), but the precise modification sites in KGDHC
have not been assessed. Peroxynitrite is increased in many neurodegenerative disorders including AD, Parkinson Disease,
multiple sclerosis, and amyotrophic lateral sclerosis (46). The
combination of Blue-native and SDS-gel electrophoresis with
mass spectrometry analysis revealed that peroxynitrite-induced nitration occurred only in two tyrosine residues in E1k
and E3 subunit, and one tyrosine in E2k even though there are
multiple tyrosine residues in KGDHC (31 tyrosine in E1k, 5 in
E2k, and 11 in E3). PTM of a specific protein does not occur
randomly. The abundance of a protein or the number of tyrosine residues in a protein cannot predict whether it is a target
for PTM (47– 49). For example, only 2 out of 18 tyrosines are
nitrated in human serum albumin following treatment with
peroxynitrite (50). The sites of PTM are likely to be determined
by the protein secondary structure and the local environment
of the tyrosine residue (48, 49).
Whether these nitration sites in KGDHC can be directly
coordinated with the loss of KGDHC activity is unknown. The
present studies did not reveal any modification of the active
sites of the three proteins of the complex. Active site studies of
all three of these large proteins with multiple copies in the complex are difficult. Most of the active sites studies are performed
with KGDHC purified from E. coli. For example, histidine 260,
298, and 729 as well as serine 321 in E1k appear to confer substrate specificity and the capacity to accommodate the TCA
metabolite oxaloacetate (51). Histidine 375, threonine 323, and
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aspartate 379 are involved in E2k active site (52). The denitration of the nitrated tyrosine residues in KGDHC correlates well
with the reversal of diminished KGDHC activity. This suggests
the importance of these tyrosine residues. Thus, site-directed
mutagenesis studies on KGDHC are essential to pinpoint
whether nitration of the specific residue of KGDHC we identified are responsible for the loss of activity.
The present studies provide the first evidence that KGDHC
can be nitrated in cells. The nitration correlates with the
changes in activity. Whether peroxynitrite also induces nitration of KGDHC in N2a cells was first tested by immunodetection of nitrated KGDHC from highly purified KGDHC from
treated N2a cells and then further confirmed by immunoprecipitation of nitrated KGDHC with the nitrotyrosine antibody.
Colocalization of KGDHC and nitrotyrosine demonstrated by
these two means provides strong evidence that nitration of
KGDHC occurs in cellular system upon peroxynitrite exposure
and correlates with the changes in activity. The 30% reduction
in E1k mRNA level in response to peroxynitrite may also contribute to the reduction in E1k protein and the overall KGDHC
activity in addition to the nitration of KGDHC. Moreover,
other TCA cycle enzymes especially the pyruvate dehydrogenase complex (PDHC), which shares the E3 subunit with
KGDHC, are also likely to be nitrated in response to peroxynitrite and their activities may be affected. Thus, nitration and/or
other modifications of these enzymes may contribute to the
decline in the oxidative metabolism in brains from patients
with neurodegenerative diseases.
Reversal of the nitration of KGDHC would suggest that nitration may be a normal part of cell signaling. Whether the inhibition of KGDHC activity by peroxynitrite can be reversed was
tested in the semi-purified enzyme as well as in cells. With
purified enzyme, the loss of KGDHC activity is directly correlated to the increased immunoreactivity of nitrotyrosines in
response to peroxynitrite. Diminished immunoreactivity of
nitration by addition of GSH following peroxynitrite parallels
the recovery of KGDHC activity. This supports the suggestion
that nitration of KGDHC likely contributes to its inhibition.
Moreover, mass spectrometry analysis showed nitration of
tyrosine residues (Tyr-352 and Tyr-416) in the E3 subunit of
KGDHC induced by peroxynitrite was completely removed by
subsequent addition of GSH. About half of the nitration of Tyr313 in E2k was removed. The nitration of E1k was not observed
by MS in the reversal experiments with peroxynitrite and peroxynitrite/GSH. This was surprising because the nitration of
the two tyrosine residues under the conditions used in Table 1
was highly reproducible by Western and MS. The treatment
conditions were different in the two experiments. In the GSH
reversal experiment, the samples were incubated for another
extra 15 min after addition of peroxynitrite as compared with
the peroxynitrite inhibition experiment in which samples were
incubated with peroxynitrite for only 15 min. The extra 15 min
of incubation of KGDHC would increase the time for denitration (see the following paragraph). A technical factor may also
be involved. The percent nitration of Tyr-175 and Tyr-556 (19
and 23%, respectively) in E1k is low. Thus, the peptides with
nitrated tyrosine have far less chance to be recovered from pool
of the same peptides without nitration.
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Similarly, peroxynitrite inhibited KGDHC activity in N2a
cells. Further treatment of cells with NAC, a precursor of GSH,
rescued KGDHC activity to near control level. Reversal of
KGDHC activity in both isolated enzyme and in cells by glutathione following peroxynitrite indicates a direct interaction of
the enzyme complex with GSH. No changes in E1k, E2k mRNA
levels and a slight reduction in the E3 mRNA level after NAC
treatment further support the direct interaction of KGDHC
with GSH.
The partial removal of nitration of KGDHC is consistent with
the presence of a denitrase activity since it is difficult to chemically remove a nitro group. This is supported by our results that
GSH is not able to diminish the nitration of actin induced by
peroxynitrite (data not shown). Hence, the de-nitration of
KGDHC is not a simple chemical removal of the nitro group by
GSH. Interestingly, E3 of KGDHC in the presence of biological
reducing agents represents a possible reducing system capable
of decreasing the nitrative damage of DNA and proteins. For
example, the E3 component of KGDHC can act as a denitrase in
the presence of cofactors of NAD(P)H or dihydrolipoic acid
(53). In the absence of E3, these substrates could not act as
denitrases. The efficiency of the E3 denitrase activity could be
increased by other compounds such as lipoic acid, or by including an NAD(P)H regenerating system. Whether glutathione
can directly or indirectly act as a cofactor or activator has not
been tested. Glutathione, a tripeptide composed of L-glutamate,
L-cysteine, and glycine, is considered to be the most important
endogenous intracellular antioxidant or reducing agent in
mammalian cells (54, 55). Increasing GSH by NAC, a precursor
of glutathione, in mammalian cells and animals has been shown
to protect cells and animals from oxidative stress and toxicity
(56, 57). Treatment of cultured HepG2 cells with 4-hydroxynonenal (HNE) resulted in a significant reduction of
PDHC and KGDHC activities. Lipoyl compounds afforded protection from HNE-induced inhibition of PDHC. This protection was higher in the presence of cysteine and GSH (58). Thus,
reversal of KGDHC activity in the presence of GSH in either
purified enzyme or cells is consistent with denitration catalyzed
by E3. In addition to its possible contribution to decreased
metabolism, the diminished KGDHC activity in AD would also
have lower denitrase activity, which is consistent with increased
nitrated proteins in AD.
In summary, the present study revealed the precise nitration
on the tyrosine residues in KGDHC treated with peroxynitrite.
The nitration can be partially reversed by subsequent addition
of GSH. KGDHC is likely to contribute to its reversal by acting
as a denitrase in the presence of reduced glutathione. The data
suggest similar changes occur in a neuronal cell line.
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